Scancell – Phase I/II trial update and company chat
As expected, Scancell Holdings (SCLP) delivered an RNS update on its ongoing Phase I/II SCIB-1 drug trials yesterday morning, following its presentation on Monday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The meeting itself has generated plenty of headlines, with lots of froth about a new cure for cancer from immunotherapy – the space in which Scancell operates: SCIB-1 is a treatment for melanoma. So what of the new data?


